These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10210 related articles for article (PubMed ID: 12795336)
1. New prognostic factors and developing therapy of cutaneous melanoma. Vihinen PP; Pyrhönen SO; Kähäri VM Ann Med; 2003; 35(2):66-78. PubMed ID: 12795336 [TBL] [Abstract][Full Text] [Related]
2. What is the role of sequential reverse-transcriptase polymerase chain reaction analysis of melanoma-specific mRNA in the peripheral blood of melanoma patients? Quaglino P; Osella-Abate S; Savoia P; Bernengo MG; Cappello N; Cavallo F J Clin Oncol; 2007 Mar; 25(9):1140-1; author reply 1141-2. PubMed ID: 17369579 [No Abstract] [Full Text] [Related]
3. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma. Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648 [TBL] [Abstract][Full Text] [Related]
4. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
5. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930 [TBL] [Abstract][Full Text] [Related]
7. [Molecular classification and markers of malignant melanoma]. Tímár J; Hársing J; Somlai B Magy Onkol; 2013 Jun; 57(2):73-8. PubMed ID: 23795351 [TBL] [Abstract][Full Text] [Related]
8. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538 [TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Schultz ES; Diepgen TL; Von Den Driesch P Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794 [TBL] [Abstract][Full Text] [Related]
10. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178 [TBL] [Abstract][Full Text] [Related]
11. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447 [TBL] [Abstract][Full Text] [Related]
12. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396 [TBL] [Abstract][Full Text] [Related]
13. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Brownbridge GG; Gold J; Edward M; MacKie RM Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559 [TBL] [Abstract][Full Text] [Related]
15. Circulating serologic and molecular biomarkers in malignant melanoma. Palmer SR; Erickson LA; Ichetovkin I; Knauer DJ; Markovic SN Mayo Clin Proc; 2011 Oct; 86(10):981-90. PubMed ID: 21964175 [TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723 [TBL] [Abstract][Full Text] [Related]